Global Head @Sanofi: Computational & AI Strategy, AI/ML, Data Science, Bioinformatics & Drug Discovery. Ex @AstraZeneca @MayoClinic @Philips @mountsinainyc
Refining therapeutic targeting of interleukin-6 by signalling mode selectivity
https://t.co/btpDjjnyDD
https://t.co/cm9hLb8DJ4
This new Review discusses how understanding of signalling mechanisms of the cytokine IL-6 could guide the discovery of safer and more effective drugs
There's been steady progress using organs in a dish—organoids— for medical research. But now there's the immunoid to enhance our understanding of the complex immune system in people, and at the individual level. @CellStemCell .
https://t.co/OockgXIcqA
Almost every paper on polygenic risk scores now reminds us that PRS should be adapted to ancestry. A new @NatureGenet study suggests another important dimension. Age.
The authors studied BMI in 62,276 children across 11 age points from 6 weeks to 8 years. They identified 624 independent signals in the longitudinal analysis. Almost one third did not show the same effect in adults! For 165 signals the association disappeared and for 29 the effect reversed direction.
A striking example is PCSK1. One variant increased BMI at around 8 months but was associated with lower BMI in adults. This fits its biology well because PCSK1 processes multiple hormones and neuropeptides and its role changes across development.
The same pattern was seen with polygenic scores. At 8 to 12 months an age-matched genome-wide PGS explained 10.9% of BMI variance. A PGS trained on adult BMI explained only 1.3%. More than an eightfold difference.
The underlying biology was familiar. The leptin melanocortin pathway was strongly enriched but different genes had different temporal profiles. LEPR and PCSK1 were more important early in life while MC4R POMC and BDNF showed more persistent effects.
Signals were also found near GLP1R and GIPR. Some GLP1R variants acted mainly in early childhood. This is especially interesting because GLP1R is the receptor targeted by semaglutide in Ozempic.
Similar results were seen for rare variants in nearly 480,000 genomes. The authors also found parent-of-origin effects. For example KLF14 acted mainly when the allele was inherited from the mother which fits its known imprinting.
To me, this makes it clear that PRS may need to be adapted not only to ancestry but also to age. The difference can be dramatic. In infancy the right age-specific score explained more BMI variation than score trained in adults. The genome stays the same. Its effects do not.
https://t.co/9G5JMnKhXr
#GWAS #PRS #adiposity #BMI #snRNA
We're missing out on the value of genomics in medical practice. The cost (not charge) to do a polygenic risk score for all these diseases (Figure) and more is only $20 and they are informative for high-risk (top 5%) across ancestries
A new review @NEJM
https://t.co/2BRwI2Tu7e
Could regulatory T cells (Tregs) shift disease treatment from broad immunosuppression to precision tolerance?
Register ➡️ https://t.co/g7srMIGDfC
#FrontiersIn#Immunology
An analysis of FDA-approved drugs reveals uneven timing and concentration of revenue life cycles across modalities and therapeutic areas, offering evidence to guide innovation strategy and policy design in a post-Inflation Reduction Act world https://t.co/eUx8WTq5Sp
https://t.co/lQyhfNuMLe
A survey of biological foundation models reveals current trends and provides an outlook for future developments in this rapidly evolving field https://t.co/NJgLVp5ATE
https://t.co/oZdsy9HJEg
Context-aware ontology-guided healthcare learning model for performance and interpretability - Asthma disease as a case study https://t.co/NyhlKl6rrZ #ScholarAlerts
Generative AI-augmented transcriptomic and microbiome analysis across inflammatory and fibrotic disease states in Crohn's disease - https://t.co/EKDagflzmJ #ScholarAlerts